| Literature DB >> 35463817 |
Fatemeh Heidary1,2, Mehdi Tourani3,2, Fatemeh Hejazi-Amiri4, Seyyed Hossein Khatami5, Navid Jamali6, Mortaza Taheri-Anganeh7.
Abstract
Lung cancer is the most common type of tumor worldwide. Non-small-cell lung carcinoma (NSCLC) is considered any epithelial cell-related lung cancer, which includes more than 85% of all lung cancer cases. NSCLC is less responsive to chemotherapy than SCLC. Therefore, the need for other treatments has become more pronounced and immunotherapy has gained increasing attention as a promising therapy in recent years. The current study aimed to design a multi-epitope peptide vaccine targeting main cancer/testis antigens of SP17, AKAP4, and PTTG1, which have a major function in tumor cell proliferation invasion. The protein vaccine was constructed using the rigorous immunoinformatics analysis and investigation of several immune system parameters, considering B cell epitopes and CD4 and CD8 induced epitopes as the most important cells to respond to cancer cells. Inverse translation and optimization of codons were performed to have the designed protein's cloning as well as expression potential in E.coli. Physicochemical, antigenic, and allergenic features were assessed to confirm the safety and immunogenicity of the vaccine. The secondary and tertiary structures were predicted. Finally, intrinsic disorder and 3D model refinement and validation were performed to eliminate structural problems. The designed construct had a stable structure that could be an antigen and stimulate the immune system and not be an allergen. The built model 3D structure was valid and stable. Further investigations are needed to approve the safety and immunogenic property of this new vaccine for NSCLC before it can be used in patients.Entities:
Keywords: Bioinformatics; Epitope Vaccine; Lung cancer
Year: 2022 PMID: 35463817 PMCID: PMC9012431 DOI: 10.22099/mbrc.2022.42468.1697
Source DB: PubMed Journal: Mol Biol Res Commun ISSN: 2322-181X
TTFrC MHC-II binding peptides determined by RANKPEP
|
|
|
|
|---|---|---|
| NDIISDISGFNSSVITYPDAQLVPGINGKAIHLVNNE | 40 | 66 |
| IEYNDMFNNFTVSFWLRVPKVSASLEQYGT | 78 | 108 |
SP17 MHCI and II predicted epitopes
|
|
|
|
|
|
|
|---|---|---|---|---|---|
|
|
| ||||
|
| H-2-Db | 34 | 43 | NIPAFAAAYF | 1.4 |
| H-2-Dd | 38 | 47 | FAAAYFESLL | 2.75 | |
| H-2-Kb | 37 | 46 | AFAAAYFESL | 2.85 | |
|
|
| ||||
|
| H2_Db | 34 | 43 | NIPAFAAAYF | 20.364 |
| H2_Dd | 30 | 39 | EQPDNIPAF | 18.510 | |
| H2_Kb | 39 | 48 | AAAYFESLL | 15.201 | |
| HLA Class- II |
| Core reliability score | |||
|
| 113 | 127 | KEEVAAVKIQAAFRG | 0.06 | |
| 29 | 43 | REQPDNIPAFAAAYF | 1.15 | ||
|
|
|
| |||
| H-2-IAd | 29 | 38 | REQPDNIPA | 11.704 | |
| H-2-IAb | 116 | 125 | VAAVKIQAA | 11.24 | |
AKAP4 MHCI and II predicted epitopes
|
|
|
|
|
|
|
|---|---|---|---|---|---|
|
|
| ||||
|
| H-2-Db | 159 | 168 | YADQVNIDYL | 0.16 |
| H-2-Dd | 18 | 27 | RSHRGVCKV | 0.23 | |
| H-2-Kb | 218 | 227 | SFYVNRLSSL | 0.32 | |
|
|
| ||||
|
| H2_Db | 206 | 215 | ISPDGECSI | 22.365 |
| H2_Dd | 213 | 222 | SIDDLSFYV | 20.369 | |
| H2_Kb | 22 | 31 | KSQSLSYASL | 18.325 | |
|
|
|
| |||
|
| H-2-IAd | 221 | 235 | VNRLSSLVIQMAHKE | 0.68 |
| H-2-IAb | 205 | 220 | VISPDGECSIDDLSF | 0.51 | |
|
|
|
| |||
| H-2-IAd | 205 | 214 | VISPDGECS | 6.678 | |
| H-2-IAb | 736 | 745 | FRGTRCIHS | 5.255 | |
PTTG1 MHCI and II predicted epitopes
|
|
|
|
|
|
|
|---|---|---|---|---|---|
|
|
| ||||
|
| H-2-Db | 42 | 51 | STPRFGKTFD | 2.2 |
| H-2-Dd | 170 | 179 | PSPPWESNLL | 1.15 | |
| H-2-Kb | 114 | 123 | IEKFFPFNPL | 1.3 | |
|
|
| ||||
|
| H2_Db | 40 | 49 | QVSTPRFGK | 25.366 |
| H2_Dd | 27 | 36 | GSGPSIKAL | 21.324 | |
| H2_Kb | 159 | 168 | FQLGPPSPV | 22.326 | |
|
|
|
| |||
|
| H-2-IAd | 155 | 169 | LEKLFQLGPPSPVKM | 0.83 |
| H-2-IAb | 46 | 60 | FGKTFDAPPALPKAT | 0.93 | |
|
|
|
| |||
| H-2-IAd | 50 | 59 | FDAPPALPK | 11.84 | |
| H-2-IAb | 158 | 167 | LFQLGPPSP | 5.289 | |
Predicted T cell epitopes using different servers
|
|
|
|
|
|---|---|---|---|
|
| |||
|
| 35 | IPAFAAAYF | 0.97/0.92642045 |
|
| 118 | AVKIQAAFR | 0.94/0.46358695 |
|
| 30 | EQPDNIPAF | 0.58/0.72258157 |
|
| |||
|
| 18 | RSHRGVCKV | 0.98/0.98838417 |
|
| 206 | ISPDGECSI | 0.80/0.91083083 |
|
| 213 | SIDDLSFYV | 0.92/0.77818421 |
|
| |||
|
| 40 | QVSTPRFGK | 0.92/0.68594268 |
|
| 27 | GSGPSIKAL | 0.97/0.4606087 |
|
| 159 | FQLGPPSPV | 0.96/0.45444044 |
Figure 1Graphical results for secondary structure prediction of chimeric protein
Figure 2Predicted structure of constructed protein using I-TASSER and Phyre2 software. The three-dimensional structure showed a protein with three main domains linked together with appropriated linker
Figure 3Validation of protein 3D model, before and after refinement by Ramachandran plot. (A) In initial model, 276 (76.2%), 48 (13.3%) and 38 (10.5%) of residues were located in favored, allowed and outlier regions, respectively. (B) In refined model, in refined model, 326 (90.1%), 26 (7.2%) and 10 (2.8%) of residues were located in favored, allowed and outlier regions, respectively
Figure 4Tertiary structure of modeled vaccine before refinement (Left). Superimposition of tertiary structure of modeled vaccine after refinement (Right).
Figure 5Intrinsically disorder regions. Amino acids in the input sequence were considered disordered when the black line is above the red line